

Press Release Archives

July 14, 2003

The units of Liquid Benchmark Exchange Traded Scheme (Liquid BeES)

The units of Liquid Benchmark Exchange Traded Scheme (Liquid BeES) shall be admitted to dealings on the Exchange w.e.f. July 16, 2003. These units shall be traded in Rolling Settlement in dematerialised form only. The ISIN corresponding to these units is INF732E01037.

[Top](#)

Press reports regarding M/s. Arvind Remedies Ltd.

The press had reports on July 11, 2003 that Arvind Remedies Limited is planning to set up a new manufacturing unit in Chennai at an investment of Rs. 50 crore. Further, the company may also go in for a rights issue.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Arvind Remedies Limited has vide its letter inter-alia stated, "We would like to clarify that the proposal as stated in the news item regarding setting up of new manufacturing unit is in a very nascent state and nothing has been crystallized yet in this regard. Further, we also wish to state that the proposal has not been deliberated or discussed at our board meeting. As regards the statement in the news item regarding the company going in for rights issue, we would like to clarify that it was only one of the option of funding for the company in case of an expansion plan as stated above. However, we wish to inform you that we would definitely keep the exchange posted immediately as and when any decisions are taken by the board on the above matters."

[Top](#)

Press reports regarding M/s. Elder Pharmaceuticals Ltd.

The press had reports that Elder Pharmaceuticals Limited has entered into manufacturing and marketing joint ventures with five multinational pharma firms.

The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company.

Elder Pharmaceuticals Limited has vide its letter inter-alia stated, "At the outset let us clarify that the Company is not entering into any Joint Ventures as reported in the press but these are only technical collaborations with licensing arrangements. Out of these the tie-up with Ferrer and Covex was already reported in the press in April 2003. Similar arrangements are being entered into with a few more multinational companies in the normal course of business. The tie-ups are of no immediate benefit to the Company as the Company proposes to launch some of the licensed products only in a span of next 5-8 months. Also, even as introduction of the new molecules would mean entry into a new market for the Company, there are other players already existing in the subject market segment. The manufacturing facilities at Patalganga for bulk drugs are ready and the Company is exploring the possibilities for their lease to multinational companies on contract manufacturing. Only after the commercials are worked out that the Company would be in a position to take a final decision in the matter. With a view to reducing the interest cost for the Company, restructuring of the debts is planned by replacing existing debts with dollar loans or low cost rupee loans. Also being explored is the equity route for replacing the existing debts as well as for funding of the expansion plans. However these are all in planning stage and no concrete plans

have been finalized."

[Top](#)

The Exchange has successfully completed its 847th Normal Settlements

The Exchange has successfully completed its 847th Normal Settlement (Rolling T+2 following SEBI directive) since inception i.e., Settlement Number N – 2003132 on July 14, 2003. The settlement statistics are as follows:

Particulars	Values
	N - 2003132
Total traded quantity (lakhs)	2707.39
Total traded value (Rs. In Crores)	4235.13
Total value of the settlement (Securities) (Rs. In Crores)	851.84
Total value of the settlement (Funds) (Rs. In Crores)	326.09
Shortages for the settlement	0.77%
% of Delivery (No. of shares delivered / No. of shares traded)	27.61%

Retail Debt Market has completed its 121st settlement, details of which are as follows :

Settlement No.	Traded Value	Settlement Value	
		Securities	Funds
2003132	NIL	NIL	NIL

[Top](#)